We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

96 hedge funds and large institutions have $103M invested in Cartesian Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $603K | Put options by funds: $257K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

29% more capital invested

Capital invested by funds: $79.7M → $103M (+$23.5M)

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

4% more funds holding

Funds holding: 92 → 96 (+4)

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

0.06% more ownership

Funds ownership: 1.33% → 1.39% (+0.06%)

Holders
96
Holders Change
+4
Holders Change %
+4.35%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
20
Increased
27
Reduced
26
Closed
16
Calls
$603K
Puts
$257K
Net Calls
+$346K
Net Calls Change
+$171K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.49M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.93M
3
Marshall Wace
Marshall Wace
United Kingdom
+$1.59M
4
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$1.32M
5
Two Sigma Investments
Two Sigma Investments
New York
+$1.29M

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$3.66M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$1.69M
3
Morgan Stanley
Morgan Stanley
New York
-$1.53M
4
KPF
K2 Principal Fund
Ontario, Canada
-$1.33M
5
ECM
Endurant Capital Management
California
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
26
CM Management
Florida
$984K – – –
Deutsche Bank
27
Deutsche Bank
Germany
$914K +$4.67K +85 +0.5%
DZ Bank
28
DZ Bank
Germany
$866K +$967K +17,601 New
State Street
29
State Street
Massachusetts
$696K +$70.3K +1,280 +10%
IA
30
IFP Advisors
Florida
$566K +$28.4K +518 +49%
ABG
31
Ally Bridge Group
New York
$548K +$612K +11,142 New
First Trust Advisors
32
First Trust Advisors
Illinois
$494K +$552K +10,042 New
Ameriprise
33
Ameriprise
Minnesota
$466K -$15.9K -290 -3%
FAM
34
Fred Alger Management
New York
$361K -$2.2K -40 -0.5%
Northern Trust
35
Northern Trust
Illinois
$350K +$27K +491 +7%
IIM
36
Ironwood Investment Management
Massachusetts
$327K +$934 +17 +0.3%
XT
37
XTX Topco
Cayman Islands
$314K +$215K +3,910 +158%
Goldman Sachs
38
Goldman Sachs
New York
$246K -$206K -3,755 -43%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$241K -$22K -401 -8%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$229K +$256K +4,655 New
Man Group
41
Man Group
United Kingdom
$223K +$249K +4,539 New
CIC
42
Cornercap Investment Counsel
Georgia
$165K +$185K +3,362 New
CANY
43
Caxton Associates (New York)
New York
$159K +$178K +3,240 New
Morgan Stanley
44
Morgan Stanley
New York
$150K -$1.53M -27,922 -90%
PCS
45
Personal CFO Solutions
New Jersey
$141K +$27.5K +500 +21%
Bank of America
46
Bank of America
North Carolina
$131K +$33.7K +614 +30%
CSS
47
Cubist Systematic Strategies
Connecticut
$126K +$32.3K +588 +30%
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$124K +$1.37K +25 +1%
Bank of New York Mellon
49
Bank of New York Mellon
New York
$121K +$66.8K +1,216 +97%
TRCT
50
Tower Research Capital (TRC)
New York
$102K +$30.7K +559 +37%
1
2
3 4 5

RNAC Hedge Fund Activity: Q3 2022 in Review

96 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2022, worth a combined $103M — up 29% from $79.7M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RNAC positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 26 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.49M. The largest seller was Mangrove Partners, cutting an estimated $3.66M.

  • 96 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2022, up from 92 in Q2 2022.
  • Funds reported $103M of Cartesian Therapeutics stock for Q3 2022, up 29% quarter-over-quarter.
  • 20 funds opened new Cartesian Therapeutics positions in Q3 2022 and 16 closed out, a net change of +4 holders.
  • The largest Cartesian Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $6.49M added.
  • The largest Cartesian Therapeutics seller in Q3 2022 was Mangrove Partners, an estimated $3.66M sold.

Based on aggregated 13F filings for Q3 2022.